SCHEMBL16239166

SCHEMBL16239166

C=Cc1cccnc1C(=O)Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
CYP3A4 P08684 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
BLM P54132 1/20 0.40
AGER Q15109 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TLR7 Q9NYK1 1/20 0.36
TRIM24 O15164 1/20 0.36
TRIM33 Q9UPN9 1/20 0.36
CYP1A2 P05177 1/20 0.36
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NFE2L2 Q16236 2/20 0.33
MYC P01106 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
P2RX7 Q99572 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL754122 0.83 KDM4E (0.55) KDM4EALDH1A1MAPTL3MBTL1CYP3A4
Hydrochloric Acid SCHEMBL16239168 0.81 KDM4E (0.53) KDM4EALDH1A1MAPTL3MBTL1CYP3A4
SCHEMBL31628026 0.81 ALDH1A1 (0.41) KDM4EALDH1A1MAPTL3MBTL1CYP3A4
SCHEMBL2840909 0.81 KDM4E (0.40) KDM4EALDH1A1MAPTL3MBTL1CYP3A4
SCHEMBL16239167 0.81 L3MBTL1 (0.37) KDM4EALDH1A1MAPTL3MBTL1CYP3A4
SCHEMBL2148128 0.77 L3MBTL1 (0.37) KDM4EALDH1A1MAPTL3MBTL1CYP3A4
SCHEMBL13388358 0.77 MAPT (0.37) KDM4EALDH1A1MAPTL3MBTL1CYP3A4
SCHEMBL535731 0.77 L3MBTL1 (0.55) KDM4EALDH1A1MAPTL3MBTL1CYP3A4
SCHEMBL13379447 0.77 MAPK1 (0.39) KDM4EALDH1A1MAPTL3MBTL1CYP3A4
SCHEMBL18901693 0.76 ALDH1A1 (0.33) KDM4EALDH1A1MAPTL3MBTL1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240417379-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2024-12-19 US disclosed
US-12116351-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2024-10-15 US disclosed
US-20220380322-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2022-12-01 US disclosed
US-11434207-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2022-09-06 US disclosed
US-20200223806-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2020-07-16 US disclosed
US-10633349-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2020-04-28 US disclosed
US-20180201587-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2018-07-19 US disclosed
US-9969700-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD. (JP) 2018-05-15 US disclosed
EP-2803662-B1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO (JP) 2017-03-01 EP disclosed
US-20160280667-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2016-09-29 US disclosed
US-9382236-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2016-07-05 US disclosed
US-20140357858-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2014-12-04 US disclosed
EP-2803662-A1 P2X4 RECEPTOR ANTAGONIST Nippon Chemiphar Co., Ltd. (JP) 2014-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380322-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 KDM4E 2376/4885ALDH1A1 3019/4885MAPT 4724/4885
US-20240417379-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 KDM4E 2520/4885ALDH1A1 3045/4885MAPT 4732/4885
US-12116351-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 KDM4E 2376/4885ALDH1A1 3019/4885MAPT 4724/4885
US-20160280667-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 KDM4E 2392/4885ALDH1A1 3013/4885MAPT 4720/4885
US-20140357858-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 KDM4E 2376/4885ALDH1A1 3019/4885MAPT 4724/4885
US-20200223806-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 KDM4E 2376/4885ALDH1A1 3019/4885MAPT 4724/4885
US-11434207-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 KDM4E 2376/4885ALDH1A1 3019/4885MAPT 4724/4885
US-10633349-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 KDM4E 2376/4885ALDH1A1 3019/4885MAPT 4724/4885
US-20180201587-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 KDM4E 2376/4885ALDH1A1 3019/4885MAPT 4724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.